ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation ("Algoma†or "the Company†) (TSX: ALC), a leading provider of marine transportation services, today announced it has entered into a definitive agreement to acquire Mainstay Maritime Inc.'s ("Mainstay†) three Canadian operating companies and associated fleet of six Canadian-flagged vessels. Mainstay, formerly Rand Logistics, Inc., operates one of the largest Jones Act-compliant fleets serving the Great Lakes, ...

Mainstay Maritime Announces Agreement to Sell Canadian Operating Companies and Fleet to Algoma Central Corporation [Accessibility Statement] Skip NavigationPositions Company to Deepen Investment in Core U.S. Jones Act Operations, Building on Robust Demand for Reliable, U.S. Jones Act Marine Great Lakes ShippingWILLIAMSVILLE, N.Y., Feb. 27, 2026 /PRNewswire/ -- Mainstay Maritime Inc. ("Mainstay"), a leading marine infrastructure company specializing in the movement of dry bulk and liquid cargos throughout th ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alongs ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsDan Cravens - Vice President and Head of Investor RelationsDavid Endicott - CEOGraham Doyle - Executive Director and Head of European MedTechIssie Kirby - VP of Equity ResearchPatrick Wood - Managing Director and Head of the U.S. Medical Technology Equity Research TeamTim Stonesifer - CFOTom Stephan - VP of Healthcare Equity ResearchVeronika Dubajova - Managing DirectorConference Call ParticipantsAnthony Petrone - Manag ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsDan Cravens - Vice President and Head of Investor RelationsDavid Endicott - CEOGraham Doyle - Executive Director and Head of European MedTechIssie Kirby - VP of Equity ResearchPatrick Wood - Managing Director and Head of the U.S. Medical Technology Equity Research TeamTim Stonesifer - CFOTom Stephan - VP of Healthcare Equity ResearchVeronika Dubajova - Managing DirectorConference Call ParticipantsAnthony Petrone - Manag ...

Alcon (NYSE:ALC) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker10Greetings. Welcome to Alcon fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to Dan Cravens, Vice President and Head of In ...

Key Takeaways Alcon's Q4 core EPS rose 8.3% Y/Y but missed, as revenues grew 9%, and shares fell 3%.ALC's Surgical sales climbed 9%, led by equipment launches and PanOptix Pro growth.Alcon projects 2026 sales growth of 5%-7% and core EPS growth of 9%-12%.Alcon, Inc. (ALC)  delivered fourth-quarter 2025 core earnings per share (EPS) of 78 cents, up 8.3% from the year-ago quarter’s figure. At the constant exchange rate or CER, the figure rose 2% year over year. The metric missed the Zacks Consensus Estimate b ...

Fourth-Quarter and Full-Year 2025 Results February 24, 2026 1 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "bel ...

Core Viewpoint - Alcon forecasts sales growth for 2026 in line with market estimates, driven by new product launches and an expected expansion in operating margin, indicating confidence in improved profitability [1]. Sales Growth and Financial Guidance - Alcon anticipates constant-currency sales growth of 5% to 7%, aligning with analysts' average revenue estimate of $11.13 billion [2]. - The company expects tariff-related costs to range between $125 million and $175 million in 2026, after mitigation actions [2]. Market Dynamics - Growth in China is expected to be sensitive to volume-based procurement initiatives and broader economic conditions [3]. - Alcon experienced strong procedural demand in cataract surgery, which is considered a nondiscretionary procedure for aging populations [3]. Quarterly Performance - Surgical sales increased by 9% to $1.55 billion in Q4, with a notable 21% growth in equipment sales due to recent product launches, including the Unity surgery tools platform [4]. - Consumables, which provide recurring revenue, rose by 8% [4]. - The operating margin decreased to 11.6% in the quarter from 15.9% a year earlier, attributed to increased spending on new product launches and higher research-and-development and tariff-related costs [4]. Investor Focus - Investors are likely to monitor whether the growth momentum from products like PanOptix Pro and newer equipment platforms can be sustained through 2026, especially amid supply-chain and pricing pressures [5].

Core Insights - Alcon reported $2.7 billion in revenue for Q4 2025, marking a year-over-year increase of 9.1% and an EPS of $0.78, up from $0.72 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate by 0.2%, while the EPS also missed the consensus estimate by 0.76% [1] Financial Performance Metrics - Total Surgical Equipment/Other net sales were $277 million, a 21% increase year-over-year, but slightly below the average estimate of $277.54 million [4] - Total Surgical Implantables net sales reached $474 million, reflecting a 4% year-over-year increase, but below the estimated $482.1 million [4] - Total Surgical net sales amounted to $1.55 billion, an 8.6% year-over-year increase, slightly under the average estimate of $1.56 billion [4] - Total Vision Care net sales were $1.16 billion, a 9.8% increase year-over-year, exceeding the average estimate of $1.15 billion [4] - Total Surgical Consumables net sales were $794 million, a 7.6% year-over-year increase, just below the average estimate of $796.13 million [4] - Total Vision Care Contact Lenses net sales were $683 million, a 7.1% increase year-over-year, slightly below the average estimate of $687.14 million [4] - Total Vision Care Ocular Health net sales reached $474 million, a 13.9% year-over-year increase, surpassing the average estimate of $462.7 million [4] - Other revenues were reported at $16 million, a significant decline of 36% year-over-year, and below the estimated $26.18 million [4] - Overall net sales matched the average estimate of $2.7 billion [4] Stock Performance - Alcon shares have returned +2.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a -1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]